Cargando…

Life-threatening “hyper-progression” on immunotherapy revealed as pseudo-progression in DNA mismatch repair deficiency: a case report

BACKGROUND: Distinguishing pseudo-progression from true progression on immunotherapy remains a clinical challenge. Clinical tools to aid in this task are currently lacking. DNA mismatch repair (MMR) status is a known predictive marker for anti-programmed death (PD)-1 therapy, but its role in helping...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Mojun, Ganesan, Chitra, Flanagan, Siobhan, Yoon, Harry H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10007936/ https://www.ncbi.nlm.nih.gov/pubmed/36915442 http://dx.doi.org/10.21037/jgo-22-709

Ejemplares similares

Larotrectinib in Mismatch-Repair-Deficient TRK Fusion-Positive Metastatic Colon Cancer After Progression on Immunotherapy
por: Kasi, Pashtoon M, et al.
Publicado: (2022)

Mismatch Repair Deficiency as a Predictive Biomarker for Immunotherapy Efficacy
por: Viale, Giulia, et al.
Publicado: (2017)

Pediatric Rectal Adenocarcinoma With Mismatch Repair Deficiency Responds to Immunotherapy
por: Qureshi, Naveen, et al.
Publicado: (2023)

Immune escape and resistance to immunotherapy in mismatch repair deficient tumors
por: Mestrallet, Guillaume, et al.
Publicado: (2023)

Immunotherapy for deficient mismatch repair (dMMR) pancreatic ductal adenocarcinoma
por: Ebia, Matthew I., et al.
Publicado: (2023)

Radio-Immunotherapy: A Case Report of ‘Abscopal Hyper-Progression’?
por: Koukourakis, Ioannis M, et al.
Publicado: (2020)

Heterogeneity in the lymphocytic infiltration of deficient DNA mismatch repair colon cancers
por: Yoon, Harry H., et al.
Publicado: (2018)

DNA mismatch repair in cancer immunotherapy
por: Guan, Junhong, et al.
Publicado: (2023)

Association of the Lung Immune Prognostic Index with Immunotherapy Outcomes in Mismatch Repair Deficient Tumors
por: Auclin, Edouard, et al.
Publicado: (2021)

Survival of patients with deficient mismatch repair metastatic colorectal cancer in the pre-immunotherapy era
por: Wensink, G. Emerens, et al.
Publicado: (2020)

Novel Roles for MLH3 Deficiency and TLE6-Like Amplification in DNA Mismatch Repair-Deficient Gastrointestinal Tumorigenesis and Progression
por: Chen, Peng-Chieh, et al.
Publicado: (2008)

Mismatch repair deficiency in ovarian cancer
por: Fuh, Katherine
Publicado: (2022)

Life-Threatening Microangiopathy or Vitamin Deficiency: A Case Report of the Clinical Manifestations of Pseudo-Thrombotic Microangiopathic Anemia
por: Landry, Ian, et al.
Publicado: (2021)

Rapid disease progression in a patient with mismatch repair-deficient and cortisol secreting adrenocortical carcinoma treated with pembrolizumab
por: Casey, R.T., et al.
Publicado: (2018)

Dynamics of genomic and immune responses during primary immunotherapy resistance in mismatch repair–deficient tumors
por: Takahashi, Nobuyuki, et al.
Publicado: (2020)

Tumor Frameshift Mutation Proportion Predicts Response to Immunotherapy in Mismatch Repair‐Deficient Prostate Cancer
por: Sena, Laura A., et al.
Publicado: (2020)

The role of DNA mismatch repair in immunotherapy of human cancer
por: He, Yuchen, et al.
Publicado: (2022)

Clonal relationship and directionality of progression of synchronous endometrial and ovarian carcinomas in patients with DNA mismatch repair-deficiency associated syndromes
por: Moukarzel, Lea A, et al.
Publicado: (2020)

Biallelic Mismatch Repair Deficiency in an Adolescent Female
por: Hildreth, Amber, et al.
Publicado: (2018)

Assessment of mismatch repair deficiency in ovarian cancer
por: Crosbie, Emma J, et al.
Publicado: (2021)

Genetic Characteristics of Mismatch Repair-deficient Glioblastoma
por: KAWAGUCHI, Kei, et al.
Publicado: (2021)

Unexplained mismatch repair deficiency: Case closed
por: Eikenboom, Ellis L., et al.
Publicado: (2022)

Immunotherapy with immune checkpoint inhibitors in colorectal cancer: what is the future beyond deficient mismatch-repair tumours?
por: Huyghe, Nicolas, et al.
Publicado: (2019)

Efficacy and safety of preoperative immunotherapy in patients with mismatch repair-deficient or microsatellite instability-high gastrointestinal malignancies
por: Li, Ying-Jie, et al.
Publicado: (2023)

Efficacy of immunotherapy in mismatch repair-deficient advanced colorectal cancer in routine clinical practice. An AGEO study
por: Alouani, E., et al.
Publicado: (2023)

A life-threatening case of pseudo-aldosteronism secondary to excessive liquorice ingestion
por: McHugh, Joseph, et al.
Publicado: (2021)

Elevated MUC5AC expression is associated with mismatch repair deficiency and proximal tumor location but not with cancer progression in colon cancer
por: Rico, Sebastian Dwertmann, et al.
Publicado: (2020)

A Patient With Locally Advanced Mismatch-Repair-Deficient Pancreatic Ductal Adenocarcinoma Successfully Treated With Neoadjuvant Immunotherapy
por: Cox, Ronald E, et al.
Publicado: (2021)

A Comprehensive Biomarker Analysis of Microsatellite Unstable/Mismatch Repair Deficient Colorectal Cancer Cohort Treated with Immunotherapy
por: Élez, Elena, et al.
Publicado: (2022)

Deficient mismatch repair: Read all about it (Review)
por: RICHMAN, SUSAN
Publicado: (2015)

Low frequency of mismatch repair deficiency in gallbladder cancer
por: Goeppert, Benjamin, et al.
Publicado: (2019)

Immunoscore in mismatch repair‐proficient and ‐deficient colon cancer
por: Wirta, Erkki‐Ville, et al.
Publicado: (2017)

Clinicopathologic features of endometrial cancer with mismatch repair deficiency
por: Gordhandas, Sushmita, et al.
Publicado: (2020)

Mismatch repair deficiency occurs very rarely in seminomas
por: Dum, David, et al.
Publicado: (2021)

Vaccines for immunoprevention of DNA mismatch repair deficient cancers
por: Hernandez-Sanchez, Alejandro, et al.
Publicado: (2022)

Mismatch repair deficiency in rectal cancer: an evolving scenario
por: Longo, Federico, et al.
Publicado: (2022)

Mismatch repair deficiency is not sufficient to elicit tumor immunogenicity
por: Westcott, Peter M. K., et al.
Publicado: (2023)

Role of the VEGF ligand to receptor ratio in the progression of mismatch repair-proficient colorectal cancer
por: Eppenberger, Manuela, et al.
Publicado: (2010)

Homologous recombination-deficient tumors are hyper-dependent on POLQ-mediated repair
por: Ceccaldi, Raphael, et al.
Publicado: (2015)

Hyper-Progressive Disease: The Potential Role and Consequences of T-Regulatory Cells Foiling Anti-PD-1 Cancer Immunotherapy
por: Tay, Christopher, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_2n2jsg4qenmldql4h7s61mtiuq